Financials data is unavailable for this security.
View more
Year on year CSPC Pharmaceutical Group Ltd 's net income fell -3.58% from 6.09bn to 5.87bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 28.06% to 29.49%.
| Gross margin | 70.59% |
|---|---|
| Net profit margin | 17.28% |
| Operating margin | 22.01% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in CNYView more
In 2023, CSPC Pharmaceutical Group Ltd increased its cash reserves by 31.12%, or 2.49bn. The company earned 4.18bn from its operations for a Cash Flow Margin of 13.29%. In addition the company generated 607.27m cash from investing, though they paid out 2.30bn more in financing than they received.
| Cash flow per share | 0.1577 |
|---|---|
| Price/Cash flow per share | 32.71 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in CNYView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 37.22% while earnings per share excluding extraordinary items fell by -3.21%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 2.18% |
|---|---|
| Div growth rate (5 year) | 25.33% |
| Payout ratio (TTM) | 63.73% |
| EPS growth(5 years) | 13.99 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -15.24 |
More ▼
